Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness?

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 9-13

  Bourke, L ^a   Kirkbride, P ^b   Hooper, R ^a   Rosario, A J ^c   Chico, T J A ^d,e   Rosario, D J ^f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c General Practitioner   (United Kingdom)

^d SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

androgen deprivation; cardiovascular risk; cost effectiveness; Prostate cancer

Indexed keywords

ABIRATERONE; CABAZITAXEL; DIETHYLSTILBESTROL; ENZALUTAMIDE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MORBIDITY; MORTALITY; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SURVIVAL RATE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS; MALE; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84872523675     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.523     Document Type: Review

References (37)

1. BAUS (2009) MDT (Multi-disciplinary Team) Guidance for Managing Prostate Cancer, 2nd Edition, http://www.baus.org.uk/OneStopCMS/Core/ CrawlerResourceServer.aspx?resource=46DCF307-C35A-49DC-A434- 277247665440&mode=link&guid=20cddeffbd274b5cbec7ba0 e6f721dcc (Accessed 01/09/2012).
2. Blankfield RP (2012) Androgen deprivation therapy for prostate cancer and cardiovascular death. JAMA: the journal of the American Medical Association 307(121252); author reply 1252-1253.
3. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11): 1066-1073.
4. Bourke L, Chico TJ, Albertsen PC, Hamdy FC, Rosario DJ (2011) Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. Heart 98(5): 345-348.
5. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA: the journal of the American Medical Association 299(3): 289-295.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr. OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995-2005.
7. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135(2): 303-307.
8. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12(5): 451-459.
9. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27(1): 92-99.
10. Huggins C, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43: 209.
11. Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411-1413.
12. Keating NL, O'Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1): 39-46.
13. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4: CD006019.
14. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 60(3): 194-201.
15. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96(22): 1821-1825.
16. Martin-Merino E, Johansson S, Morris T, Garcia Rodriguez LA (2011) Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf 34(11): 1061-1077.
17. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60(3 Suppl 1): 7-11; discussion 11-2.
18. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6): 472-479.
19. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4): 572-583.
20. Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P (2012) Addition of Radiotherapy to Long-Term Androgen Deprivation in Locally Advanced Prostate Cancer: An Open Randomised Phase 3 Trial. Eur Urol 62(2): 213-219.
21. Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1: CD003506.
22. NCCN (2012) National Comprehensive Cancer Network: Clinical practice guidelines in oncology. Prostate cancer. Version 3, http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp (Accessed 01/09/2012).
23. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21): 2359-2366.
24. Payne H, Mason M (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 105(11): 1628-1634.
25. Roach 3rd M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26(4): 585-591.
26. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 367(13): 1187-1197.
27. Schroder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L (2009) Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 55(1): 14-22.
28. Shahinian VB, Kuo YF, Gilbert SM (2010) Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 363(19): 1822-1832.
29. Souhami L, Bae K, Pilepich M, Sandler H (2009) Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 27(13): 2137-2143.
30. Studer U, Whelan P, Albrecht W, Casselman J, Reijke TMD, Knönagel H, Madersbacher S, Isorna S, Sundaram SK, Collette L (2011) Long term results of immediate versus deferred androgen deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891). J Urol 185(4S): e144.
31. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24(12): 1868-1876.
32. The NHS Information Centre PSU (2010) Prescription Cost Analysis England 2010, http://www.ic.nhs.uk/webfiles/publications/007-Primary-Care/Prescribing/ Prescription-Cost-Analysis-England-2010/Prescription-Cost-Analysis-2010.pdf (Accessed 16/05/12).
33. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV (1982) Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79(5): 1658-1662.
34. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28(21): 3448-3456.
35. Verhagen PC, Schroder FH, Collette L, Bangma CH (2010) Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58(2): 261-269.
36. Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS, Oliver RT (1983) Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 286(6374): 1309-1312.
37. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660): 301-308.